^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:BDTX-1535 (EGFR inhibitor, EGFR MasterKey inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Black Diamond Therapeutics Press Release
    Title:

    Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

    Published date:
    06/27/2023
    Excerpt:
    Black Diamond Therapeutics...announced initial clinical data from the dose escalation portion of the Phase 1 clinical study of BDTX-1535….The new data from the dose escalation portion of the Phase 1 study demonstrated clinical proof of activity of BDTX-1535 in NSCLC patients harboring both acquired resistance and intrinsic driver EGFR mutations.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    3396 / 6 - Discovery of BDTX-1535, a novel 4th generation, irreversible, potent, wild type sparing EGFR MasterKey inhibitor that targets oncogenic kinase domain mutations as well as extracellular domain alterations for the treatment of NSCLC and GBM

    Published date:
    03/15/2023
    Excerpt:
    BDTX-1535 achieves potent anti-tumor activity against EGFR alterations and amplification across models including NSCLC and GBM PDX and intracranial tumors.